Rationale and results from. BRAFi and immunotherapy
|
|
- Debra Simmons
- 5 years ago
- Views:
Transcription
1 Rationale and results from emerging combinations of BRAFi and immunotherapy Antoni Ribas, M.D. rofessor of Medicine rofessor of Surgery rofessor of Molecular and Medical harmacology Director, Tumor Immunology rogram, Jonsson Comprehensive Cancer Center (JCCC) University of California Los Angeles (UCLA) Disclosures I have received honoraria from advisory boards with Roche-Genentech, h BMS, GSK, Merck, Millennium and Amgen 1
2 Combining immunotherapy and targeted therapy for melanoma? Immunotherapy Targeted therapy Combination ercent aliv ve ercent aliv ve ercent aliv ve Years Years Years Activated human lymphocytes are highly resistant to vemurafenib IC5 IC5 of human of human melanoma vs. cell lymphocytes lines vs lymphocytes exposed exposed to RG724 to LX432 x 72hx 72h 25 >25 >25 2 LX432 LX432 IC Bioluminescence cell viability assay Comin-Anduix, Chodon et al. CCR 21 5 M229 M233 BRAF V6E melanoma. GA2 GA17 H GA21 Resting lymphocytes.. GA2_ H_ Activated lymphocytes 2
3 Differential effects of BRAF inhibition in BRAF V6 mutant melanoma and activated T cells BRAF V6 mutant melanoma Activated T cells LX432 LX432 CRAF BRAF V6 CRAF BRAF V6 CRAF BRAF CRAF BRAF MEK1/2 MEK1/2 MEK1/2 MEK1/2 ERK ERK ERK ERK MAK signaling MAK signaling MAK signaling MAK signaling Modeled from Hatzivassiliou et al. Nature 21, Heidorn et al. Cell 21, oulikakos et al. Nature 21 Vemurafenib as an Immunosensitization Agent Target a key oncogenic pathway Specific cancer cell apoptotic p death Increase ligands for immune cells (tumor antigen, MHC, NK activating receptors) Not kill immune cells No interference on key signaling events in immune system cells Bollag et al. Nature 21 Flaherty et al. NEJM 21 Wargo et al. Cancer Res 21 Comin-Anduix et al. Clin Cancer Res 21 3
4 FSC-H, subset TUF V A+I AGAIN.14 Event Count: FSC-H, subset TUF LX A+I.12 Event Count: SM1: A BRAF V6E -driven Melanoma Syngeneic to Immunocompetent Mice Goel, Haluska et al. Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV6E mice. Oncogene. 29; 28 (23): BRAF V6E mutation SM1is moderately sensitive to vemurafenib SM-1 SM-1 LX432 No adverse effects against murine splenocytes ropidium Iodide M22 FL2-H M22 LX432 FL2-H LX 19.3 Annexin V 4
5 Vemurafenib inhibits oncogenic MAK signaling in SM1 but does not change gp1 melanoma antigen expression 1hr 24hr 1hr 24hr VC LX (µm) VC LX (µm) perk Erk pmek Mek TEN gp1 Tubulin VC LX (µm) VC LX (µm) pakt(ser) Akt ps6k(thr/ser) ps6k(thr) S6K Tubulin Antitumor Activity of Vemurafenib Against the SM1 BRAF V6E -driven Murine Melanoma Goel, Haluska et al. Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV6E mice. Oncogene. 29; 28 (23): SM-1: BRAF V6E mutant murine melanoma cell line syngeneic to C57BL/6 mice DMSO LX432 Effect of LX432 on Tumor Xenograft on B6-9 Average Tumor Volume (mm^3) 25 LX Days 5
6 OT-1 ACT immunotherapy+braf targeted therapy against SM1-OVA (murine melanoma driven by BRAF V6E and expressing OVA) OVA L1 L2 L3 ~ 45-5 kda LX432 Alone OT1 ACT Alone LX432 + OT1 ACT =.2 =.4 pmel-1 ACT immunotherapy+braf targeted therapy against SM1 (murine melanoma driven by BRAF V6E ) 1hr 24hr VC LX (µm) VC LX (µm) gp1 Tubulin LX432 Alone mel-1 ACT Alone LX432 + mel-1 ACT <.8 <.8 6
7 How can BRAF targeted therapy increase the activity of tumor immunotherapy? Increased antigen Cross-presentation DC Increased direct antigen presentation Activation of T cells and increased homing Decreased immune suppressive factor release BLI imaging of f-luc-labeled TCR transgenic pmel-1 lymphocyte ACT SM1 tumor No difference in the T cell expansion with the addition of vemurafenib (LX432) 7
8 H No difference in the cellintrinsic cytotoxic activity in vivo Ova control with low CFSE labeling gp1 targets with high CFSE labeling +/- LX432 mel-1 reconstituted mouse OVA peptide pulsed + pmel-1 ACT re-infusion cells Mouse: LX432+ pmel-1 ACT , subset cell OVA gp1.11 Event Count: , subset at 4.4 Event Count: gp1 peptide pulsed , subset at 5.5 Event Count: /Mock ACT , subset vc 7.7 Event Count: #1 #2 #3 6.89, subset plx at 1.1 Event Count: , subset plx at 2.2 Event Count: , subset at 6.6 Event Count: , subset plx at 3.3 Event Count: Functional analysis of TILs LX432 # #2 #3 2, subset LX4A+.8 Event Count: , subset LX4B+.1 Event Count: , subset LX1A+.2 Event Count: , subset LX1B+.4 Event Count: SSC C-H At day 5 post-act of pmel-1 and treatment with LX432, tumors were harvested and TILs isolated for intracellular IFNγ staining and FACS analysis 2 2, subset LX5A+.12 Event Count: , subset LX2+.6 Event Count: IFN-γ Treatment with vemurafenib increases the cytokine production by TILs 8
9 Conclusions Vemurafenib does not adversely effect the function of human or murine lymphocytes Combination of vemurafenib with ACT immunotherapy is mediated by improved intratumoral infiltration by activated lymphocytes: Increased IFN-g production by TILs Modulation of the tumor microenviroment? The clinical testing of a combination of vemurafenib and ipilimumab, and/or vemurafenib and ACT therapy, is warranted Acknowledgements Begonya Comin-Anduix, hd Thinle Chodon, MD, hd Stephen Mok Richard Koya, MD, hd Earl Avramis Mohammad Atefi, h.d. Charles Ng Nicholas Otte 9
Supplementary Figure 1. BMS enhances human T cell activation in vitro in a
Supplementary Figure 1. BMS98662 enhances human T cell activation in vitro in a concentration-dependent manner. Jurkat T cells were activated with anti-cd3 and anti-cd28 antibody in the presence of titrated
More informationPREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
Award Number: W81XWH-12-1-48 TITLE: Evaluation of the immunologic impact of RAF Inhibitors to Guide Optimal Combination of RAF inhibitors and Immunotherapy for the treatment of Advanced Melanoma PRINCIPAL
More informationResponse and resistance to BRAF inhibitors in melanoma
Response and resistance to BRAF inhibitors in melanoma Keith T. Flaherty, M.D. Massachusetts General Hospital Cancer Center Disclosures Roche/Genentech: consultant GlaxoSmithKline: consultant BRAF mutations
More informationCombination Approaches in Melanoma: A Balancing Act
Combination Approaches in Melanoma: A Balancing Act Antoni Ribas, MD, PhD Jonsson Comprehensive Cancer Center University of California Los Angeles Los Angeles, California Advances in the Treatment of Metastatic
More informationSupplemental Figure 1
Supplemental Figure 1 1a 1c PD-1 MFI fold change 6 5 4 3 2 1 IL-1α IL-2 IL-4 IL-6 IL-1 IL-12 IL-13 IL-15 IL-17 IL-18 IL-21 IL-23 IFN-α Mut Human PD-1 promoter SBE-D 5 -GTCTG- -1.2kb SBE-P -CAGAC- -1.kb
More informationInterleukin-2 Single Agent and Combinations
Interleukin-2 Single Agent and Combinations Michael K Wong MD PhD Norris Cancer Center University of Southern California mike.wong@med.usc.edu Disclosures Advisory Board Attendance Merck Bristol Myers
More informationHost immunity contributes to the antimelanoma activity of BRAF inhibitors
Research article Host immunity contributes to the antimelanoma activity of BRAF inhibitors Deborah A. Knight, 1,2 Shin Foong Ngiow, 1,2,3 Ming Li, 1,2 Tiffany Parmenter, 2,4 Stephen Mok, 5 Ashley Cass,
More information2/16/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery
C007: Immunology of Melanoma: Mechanisms of Immune Therapies Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los Angeles Biomedical
More informationRaising the bar: optimizing combinations of targeted therapy and immunotherapy
Editorial Page 1 of 5 Raising the bar: optimizing combinations of targeted therapy and immunotherapy Alexandre Reuben 1, Jacob Austin-Breneman 1, Jennifer A. Wargo 1,2 *, Zachary A. Cooper 1,2 * 1 Department
More informationNIH Public Access Author Manuscript Clin Cancer Res. Author manuscript; available in PMC 2015 July 01.
NIH Public Access Author Manuscript Published in final edited form as: Clin Cancer Res. 2014 July 1; 20(13): 3446 3457. doi:10.1158/1078-0432.ccr-13-2797. Effects of MAPK and PI3K Pathways on PD-L1 Expression
More informationDisclosure Information. Mary L. Disis
Disclosure Information Mary L. Disis I have the following financial relationships to disclose: Consultant for: VentiRx, Celgene, Emergent, EMD Serono Speaker s Bureau for: N/A Grant/Research support from:
More informationSupplementary Figures
Supplementary Figures Supplementary Figure 1. NKT ligand-loaded tumour antigen-presenting B cell- and monocyte-based vaccine induces NKT, NK and CD8 T cell responses. (A) The cytokine profiles of liver
More informationNormal RAS-RAF (MAPK) pathway signaling
BRAF-Mutations in Melanomas L. Mazzucchelli Istituto Cantonale di Patologia, Locarno 77. Annual Meeting Swiss Society of Pathology, Lucerne 2011 Sponsored by Roche Pharma Switzerland Melanoma has increased
More informationDendritic cells in cancer immunotherapy Aimin Jiang
Dendritic cells in cancer immunotherapy Aimin Jiang Feb. 11, 2014 Dendritic cells at the interface of innate and adaptive immune responses Dendritic cells: initiators of adaptive immune responses Dendritic
More informationCytokines: Interferons, Interleukins and Beyond. Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center
Cytokines: Interferons, Interleukins and Beyond Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center Disclosures Advisory Boards: Bristol-Myers Squibb,Amgen, Novartis, Alkermes, Infinity,
More informationNew Systemic Therapies in Advanced Melanoma
New Systemic Therapies in Advanced Melanoma Sanjay Rao, MD FRCPC Medical Oncologist (BCCA-CSI) Clinical Assistant Professor, UBC Faculty of Medicine SON Fall Update October 22, 2016 Disclosures Equity
More information2/19/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery
F141: Advanced Melanoma: Mechanisms of Immune Therapies beyond Checkpoint blockade Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los
More informationMATERIALS AND METHODS. Neutralizing antibodies specific to mouse Dll1, Dll4, J1 and J2 were prepared as described. 1,2 All
MATERIALS AND METHODS Antibodies (Abs), flow cytometry analysis and cell lines Neutralizing antibodies specific to mouse Dll1, Dll4, J1 and J2 were prepared as described. 1,2 All other antibodies used
More informationCorporate Medical Policy
Corporate Medical Policy BRAF Gene Variant Testing to Select Melanoma or Glioma Patients File Name: Origination: Last CAP Review: Next CAP Review: Last Review: braf_gene_variant_testing_to_select_melanoma_or_glioma_patients_for_targeted_
More informationSupplementary Fig. 1 p38 MAPK negatively regulates DC differentiation. (a) Western blot analysis of p38 isoform expression in BM cells, immature DCs
Supplementary Fig. 1 p38 MAPK negatively regulates DC differentiation. (a) Western blot analysis of p38 isoform expression in BM cells, immature DCs (idcs) and mature DCs (mdcs). A myeloma cell line expressing
More informationSupplementary Figure 1. IL-12 serum levels and frequency of subsets in FL patients. (A) IL-12
1 Supplementary Data Figure legends Supplementary Figure 1. IL-12 serum levels and frequency of subsets in FL patients. (A) IL-12 serum levels measured by multiplex ELISA (Luminex) in FL patients before
More informationDevelopment of Rational Drug Combinations for Oncology Indications - An Industry Perspective
Development of Rational Drug Combinations for Oncology Indications An Industry Perspective Stuart Lutzker, MDPhD Vice President Oncology Early Development Genentech Inc 1 Conventional Oncology Drug Development
More informationA Slfn2 mutation causes lymphoid and myeloid immunodeficiency due to loss of immune cell quiescence
Supplementary Information A Slfn mutation causes lymphoid and myeloid immunodeficiency due to loss of immune cell quiescence Michael Berger, Philippe Kres, Karine Crozat, Xiaohong Li, Ben A. Croker, Owen
More informationImmune surveillance hypothesis (Macfarlane Burnet, 1950s)
TUMOR-IMMUNITÄT A.K. Abbas, A.H. Lichtman, S. Pillai (6th edition, 2007) Cellular and Molecular Immunology Saunders Elsevier Chapter 17, immunity to tumors Immune surveillance hypothesis (Macfarlane Burnet,
More informationSupplemental Figure 1. Signature gene expression in in vitro differentiated Th0, Th1, Th2, Th17 and Treg cells. (A) Naïve CD4 + T cells were cultured
Supplemental Figure 1. Signature gene expression in in vitro differentiated Th0, Th1, Th2, Th17 and Treg cells. (A) Naïve CD4 + T cells were cultured under Th0, Th1, Th2, Th17, and Treg conditions. mrna
More informationSUPPLEMENTARY INFORMATION
Complete but curtailed T-cell response to very-low-affinity antigen Dietmar Zehn, Sarah Y. Lee & Michael J. Bevan Supp. Fig. 1: TCR chain usage among endogenous K b /Ova reactive T cells. C57BL/6 mice
More informationCTLA4 Blockade in Melanoma Treatment. Antoni Ribas, M.D. Associate Professor of Medicine and Surgery University of California Los Angeles.
CTLA Blockade in Melanoma Treatment Antoni Ribas, M.D. Associate Professor of Medicine and Surgery University of California Los Angeles. CTLA Negatively Modulates T-Cell Activation MHC Antigen TCR Dendritic
More informationAntitumor activity of the ERK inhibitor SCH against BRAF mutant, NRAS mutant and wild-type melanoma
Wong et al. Molecular Cancer 2014, 13:194 RESEARCH Open Access Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma Deborah JL Wong 1, Lidia Robert
More informationInnovations in Immunotherapy - Melanoma. Systemic Therapies October 27, 2018 Charles L. Bane, MD
Innovations in Immunotherapy - Melanoma Systemic Therapies October 27, 2018 Charles L. Bane, MD Melanoma Prognosis Survival at 10 years Stage I: 90% Stage II: 60% Stage III: 40% Stage IV: 10% 2 Indications
More informationCorporate Medical Policy
Corporate Medical Policy BRAF Gene Mutation Testing to Select Melanoma or Glioma Patients File Name: Origination: Last CAP Review: Next CAP Review: Last Review: braf_gene_mutation_testing_to_select_melanoma_or_glioma_patients_for_targeted_
More informationSUPPLEMENTARY INFORMATION
doi:10.1038/nature23291 Supplementary discussion part 1 Our model suggests that, in tumours that express Class 3 BRAF mutants and activated RAS, both BRAF MUT /RAF WT heterodimers and WT RAF dimers are
More informationFunctional reprogramming of the tumor stroma by IL-12 Engineered T cells is required for anti-tumor immunity. Sid Kerkar, M.D.
Functional reprogramming of the tumor stroma by IL-12 Engineered T cells is required for anti-tumor immunity Sid Kerkar, M.D. Cancer Therapies Surgery Chemotherapy Radiation Emerging Cell Based Therapy
More informationNew insights into CD8+ T cell function and regulation. Pam Ohashi Princess Margaret Cancer Centre
New insights into CD8+ T cell function and regulation Pam Ohashi Princess Margaret Cancer Centre New insights into CD8+ T cell function and regulation Pam Ohashi Princess Margaret Cancer Centre No Disclosures
More informationComplexity of intra- and inter-pathway loops in colon cancer and melanoma: implications for targeted therapies
Complexity of intra- and inter-pathway loops in colon cancer and melanoma: implications for targeted therapies René Bernards The Netherlands Cancer Institute Amsterdam The Netherlands Molecular versus
More informationHistology independent indications in oncology. The BRAF Story. Yibing Yan PhD Roche / Genentech
Histology independent indications in oncology The BRAF Story Yibing Yan PhD Roche / Genentech 1 Introduction the discovery Case study in BRAF mutant melanoma heterogeneity within the tumour variability
More informationImmunity and Cancer. Doriana Fruci. Lab di Immuno-Oncologia
Immunity and Cancer Doriana Fruci Lab di Immuno-Oncologia Immune System is a network of cells, tissues and organs that work together to defend the body against attacks of foreign invaders (pathogens, cancer
More informationLeucine Deprivation Reveals a Targetable Liability
Cancer Cell, 19 Supplemental Information Defective Regulation of Autophagy upon Leucine Deprivation Reveals a Targetable Liability of Human Melanoma Cells In Vitro and In Vivo Joon-Ho Sheen, Roberto Zoncu,
More informationSupplemental Table I.
Supplemental Table I Male / Mean ± SEM n Mean ± SEM n Body weight, g 29.2±0.4 17 29.7±0.5 17 Total cholesterol, mg/dl 534.0±30.8 17 561.6±26.1 17 HDL-cholesterol, mg/dl 9.6±0.8 17 10.1±0.7 17 Triglycerides,
More informationSupplementary Figure 1. Efficient DC depletion in CD11c.DOG transgenic mice
Supplementary Figure 1. Efficient DC depletion in CD11c.DOG transgenic mice (a) CD11c.DOG transgenic mice (tg) were treated with 8 ng/g body weight (b.w.) diphtheria toxin (DT) i.p. on day -1 and every
More informationAdoptive T Cell Therapy:
Adoptive T Cell Therapy: A Paradigm for Combination Strategies Cassian Yee MD Professor Melanoma Medical Oncology Immunology Director Solid Tumor Cell Therapy cyee@mdanderson.org skype name: tcelltherapy
More informationSupplementary Figure 1. Deletion of Smad3 prevents B16F10 melanoma invasion and metastasis in a mouse s.c. tumor model.
A B16F1 s.c. Lung LN Distant lymph nodes Colon B B16F1 s.c. Supplementary Figure 1. Deletion of Smad3 prevents B16F1 melanoma invasion and metastasis in a mouse s.c. tumor model. Highly invasive growth
More informationNK mediated Antibody Dependent Cellular Cytotoxicity in HIV infections
NK mediated Antibody Dependent Cellular Cytotoxicity in HIV infections Amy Chung Dr. Ivan Stratov Prof. Stephen Kent ADCC process consists of Target cell QuickTime and a TIFF (Uncompressed) FcγR decompressor
More informationImmunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania
Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions
More informationUpdate on Melanoma Treatment. Tara C Mitchell, MD
Update on Melanoma Treatment Tara C Mitchell, MD Overview Immune therapy update Targeted therapy update New concepts in treating melanoma What is the immune system? A complex network of protective cells
More informationAntitumor activity of the ERK inhibitor SCH against BRAF mutant, NRAS mutant and wild-type melanoma
Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma Deborah JL Wong 1, Email: dewong@mednet.ucla.edu Lidia Robert 1, Email: lrobert@mednet.ucla.edu
More informationHua Tang, Weiping Cao, Sudhir Pai Kasturi, Rajesh Ravindran, Helder I Nakaya, Kousik
SUPPLEMENTARY FIGURES 1-19 T H 2 response to cysteine-proteases requires dendritic cell-basophil cooperation via ROS mediated signaling Hua Tang, Weiping Cao, Sudhir Pai Kasturi, Rajesh Ravindran, Helder
More informationMelanoma- Fighting the Dark Side
Melanoma- Fighting the Dark Side Anna C. Pavlick, BSN, MSc, DO, MBA Professor of Medicine and Dermatology Director, NYU Melanoma Program Director, NYU Clinical Trials Office NYU Perlmutter Cancer Center
More informationBlack is the New Black or How I learned to stop worrying and love melanoma (with apologies to Dr. Strangelove)
Black is the New Black or How I learned to stop worrying and love melanoma (with apologies to Dr. Strangelove) Provincial Cancer Care Conference 2018 Ralph P.W. Wong MD FRCPC St Boniface Site Director
More informationVISTA, a novel immune checkpoint protein ligand that suppresses anti-tumor tumor T cell responses. Li Wang. Dartmouth Medical School
VISTA, a novel immune checkpoint protein ligand that suppresses anti-tumor tumor T cell responses Li Wang Dartmouth Medical School The B7 Immunoglobulin Super-Family immune regulators APC T cell Co-stimulatory:
More informationTITLE: MODULATION OF T CELL TOLERANCE IN A MURINE MODEL FOR IMMUNOTHERAPY OF PROSTATIC ADENOCARCINOMA
AD Award Number: DAMD17-01-1-0085 TITLE: MODULATION OF T CELL TOLERANCE IN A MURINE MODEL FOR IMMUNOTHERAPY OF PROSTATIC ADENOCARCINOMA PRINCIPAL INVESTIGATOR: ARTHUR A HURWITZ, Ph.d. CONTRACTING ORGANIZATION:
More informationActive STAT5 promotes long lived cytotoxic CD8 T cells that induce regression of autochthonous mouse melanoma.
Active STAT5 promotes long lived cytotoxic CD8 T cells that induce regression of autochthonous mouse melanoma. SITC 211 Grégory Verdeil No relationships to disclose T cell adoptive transfer for cancer
More informationDendritic cell subsets and CD4 T cell immunity in Melanoma. Ben Wylie 1 st year PhD Candidate
Dendritic cell subsets and CD4 T cell immunity in Melanoma Ben Wylie 1 st year PhD Candidate Melanoma Melanoma is the 4 th most common cancer in Australia. Current treatment options are ineffective resulting
More informationMind the Gap : Challenges in First-in- Man Evaluation of Immuno-Oncology Drugs
Mind the Gap : Challenges in First-in- Man Evaluation of Immuno-Oncology Drugs Ignacio Garcia-Ribas MD, PhD Senior Medical Director Early Clinical Research & Development, Oncology Therapeutic Area Takeda
More informationSupplemental materials
Supplemental materials 1 Supplemental Fig. 1 Immunogram This immunogram summarizes patient clinical data and immune parameters at corresponding time points for Patient IMF-32. The top panel illustrates
More informationSupplementary Information. Tissue-wide immunity against Leishmania. through collective production of nitric oxide
Supplementary Information Tissue-wide immunity against Leishmania through collective production of nitric oxide Romain Olekhnovitch, Bernhard Ryffel, Andreas J. Müller and Philippe Bousso Supplementary
More informationOne Moment Please. Skin Cancer. Today s Webcast Friday, 09/09/11, Noon. David Carr, MD
One Moment Please One Moment Please Skin Cancer Thomas Olencki, DO David Carr, MD Today s Webcast Friday, 09/09/11, Noon 1 New Features Enlarge Slides Links Chapters Polling Use the email function to let
More informationSupplementary Figure 1: Digitoxin induces apoptosis in primary human melanoma cells but not in normal melanocytes, which express lower levels of the
Supplementary Figure 1: Digitoxin induces apoptosis in primary human melanoma cells but not in normal melanocytes, which express lower levels of the cardiac glycoside target, ATP1A1. (a) The percentage
More informationRegulation of anti-tumor immunity through migration of immune cell subsets within the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D.
Regulation of anti-tumor immunity through migration of immune cell subsets within the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D. Professor, Departments of Pathology and Medicine Program Leader,
More informationSupplementary Figure 1
Supplementary Figure 1 # nonsynonymous mutations (tngs, 1561 genes) 600 p=0.056 500 250 200 150 100 50 0 HLA-DR (-) HLA-DR (+) Supplementary Figure 1: HLA-DR(+) melanoma cell lines are associated with
More informationCell-mediated Immunity
Cellular & Molecular Immunology Cell-mediated Immunity Nicholas M. Ponzio, Ph.D. Department of Pathology & Laboratory Medicine April 6, 2009 Today s Presentation: Overview Cellular Interactions In Humoral
More informationRXi Pharmaceuticals. Immuno-Oncology World Frontiers Conference. January 23, 2018 NASDAQ: RXII. Property of RXi Pharmaceuticals
RXi Pharmaceuticals Immuno-Oncology World Frontiers Conference January 23, 2018 NASDAQ: RXII Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationMelanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin
Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy What every patient needs to know James Larkin Melanoma Therapy 1846-2017 Surgery 1846 Cytotoxic Chemotherapy 1946 Checkpoint Inhibitors
More informationImmune Checkpoint Inhibitors Drug Combinations: Patients Relevance & Ways Forward
March 25, 2015 Immune Checkpoint Inhibitors Drug Combinations: Patients Relevance & Ways Forward Dr. Alexandre Passioukov p 1 Therapeutic efficacy of agents targeting immune checkpoints Introduction Deep
More informationBlocking antibodies and peptides. Rat anti-mouse PD-1 (29F.1A12, rat IgG2a, k), PD-
Supplementary Methods Blocking antibodies and peptides. Rat anti-mouse PD-1 (29F.1A12, rat IgG2a, k), PD- L1 (10F.9G2, rat IgG2b, k), and PD-L2 (3.2, mouse IgG1) have been described (24). Anti-CTLA-4 (clone
More informationUpdate on Melanoma. Main Themes
Update on Melanoma Antoni Ribas, M.D. Professor of Medicine, Surgery, and Medical and Molecular Pharmacology University of California Los Angeles (UCLA) and the Jonsson Comprehensive Cancer Center Main
More informationOverexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma
Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma The Harvard community has made this article openly available. Please share
More informationMst1 regulates integrin-dependent thymocyte trafficking and antigen recognition in the thymus
Mst1 regulates integrin-dependent thymocyte trafficking and antigen recognition in the thymus Yoshihiro Ueda, Koko Katagiri, Takashi Tomiyama, Kaneki Yasuda, Katsuyoshi Habiro, Tomoya Katakai, Susumu Ikehara,
More informationNatural Killer Cells: Development, Diversity, and Applications to Human Disease Dr. Michael A. Caligiuri
Natural Killer Cells: Development, Diversity, November 26, 2008 The Ohio State University Comprehensive Cancer Center The James Cancer Hospital and Solove Research Institute Columbus, Ohio, USA 1 Human
More informationA Multi-Center Phase II Study on High Dose IL-2 (HD IL-2) Sequenced with Vemurafenib in Patients with BRAF-V600E Mutation Positive Advanced Melanoma
A Multi-Center Phase II Study on High Dose IL-2 (HD IL-2) Sequenced with in Patients with BRAF-V6E Mutation Positive Advanced Melanoma Adapted from a poster presented at the ASCO 215 Joseph I. Clark 1,
More informationNature Medicine: doi: /nm.3922
Title: Glucocorticoid-induced tumor necrosis factor receptor-related protein co-stimulation facilitates tumor regression by inducing IL-9-producing helper T cells Authors: Il-Kyu Kim, Byung-Seok Kim, Choong-Hyun
More informationReviewers' comments: Reviewer #1 (Remarks to the Author):
Reviewers' comments: Reviewer #1 (Remarks to the Author): This manuscript builds on the recently published observation by the same investigators that TNBC tumors with Ras/MAPK activation have decreased
More informationSupplementary Figure 1. a. b. Relative cell viability. Nature Genetics: doi: /ng SCR shyap1-1 shyap
Supplementary Figure 1. a. b. p-value for depletion in vehicle (DMSO) 1e-05 1e-03 1e-01 1 0 1000 2000 3000 4000 5000 Genes log2 normalized shrna counts in T0 0 2 4 6 8 sh1 shluc 0 2 4 6 8 log2 normalized
More informationSummary... 2 TRANSLATIONAL RESEARCH Tumour gene expression used to direct clinical decision-making for patients with advanced cancers...
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 TRANSLATIONAL RESEARCH... 3 Tumour gene expression used to direct clinical decision-making for patients with advanced
More informationCombining ADCs with Immuno-Oncology Agents
Combining ADCs with Immuno-Oncology Agents Chad May, PhD Senior Director Targeted Immunotherapy Oncology Research Unit, Pfizer 7 th Annual World ADC October 10, 2016 Cancer-Immunity Cycle Innate Immunity
More informationSupplementary Information
Supplementary Information Supplementary Methods Assessment of clinical characteristics of the single-agent anti-pd-1 cohort Clinical data were retrospectively collected from patient record, including age,
More informationEffective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features
Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features Loretta Gammaitoni, Lidia Giraudo, Valeria Leuci, et al. Clin Cancer Res
More informationImproving Immunotherapy for Melanoma
Improving Immunotherapy for Melanoma David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/ Harvard Cancer Center Harvard Medical School Immunotherapy Improvement Model All patients All
More informationDeveloping Novel Immunotherapeutic Cancer Treatments for Clinical Use
Developing Novel Immunotherapeutic Cancer Treatments for Clinical Use Oncology for Scientists March 8 th, 2016 Jason Muhitch, PhD Assistant Professor Department of Urology Email: jason.muhitch@roswellpark.org
More informationThe Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.
Combined BRAFV600E- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer The Harvard community
More informationPushing the boundaries-targeted therapies
Pushing the boundaries-targeted therapies Professor Grant McArthur MB BS PhD Director Melanoma and Skin Cancer VCCC Parkville, Peter MacCallum Cancer Centre Lorenzo Galli Chair of Melanoma & Skin Cancers,
More informationRegulating the Regulators for Cancer Immunotherapy: LAG-3 Finally Catches Up. Drew Pardoll Sidney Kimmel Cancer Center Johns Hopkins
Regulating the Regulators for Cancer Immunotherapy: LAG-3 Finally Catches Up Drew Pardoll Sidney Kimmel Cancer Center Johns Hopkins The hostile immune microenvironment within a tumor Stat3 Stat3 NK Lytic
More informationRol de los Inhibidores de MEK Melanoma. Maria González Cao Instituto Oncologico Dr Rosell, Quiron Dexeus Barcelona
Rol de los Inhibidores de MEK Melanoma Maria González Cao Instituto Oncologico Dr Rosell, Quiron Dexeus Barcelona Index 1.- Molecular pathway 2.- MEK inhibitor drugs 3.- Preclinical and clinical data 3.1.
More informationCombination Immunotherapy Approaches Chemotherapy, Radiation Therapy, and Dual Checkpoint Therapy
Combination Immunotherapy Approaches Chemotherapy, Radiation Therapy, and Dual Checkpoint Therapy Dr. David B. Page Providence Portland Medical Center Earle A. Chiles Research Institute Funding & Disclosures
More informationLocalized Regulated Expression of IL- 12 as a Gene Therapy Approach to Cancer Immunotherapy. John A. Barrett Ph.D. Ziopharm Oncology, Boston MA 02129
Localized Regulated Expression of IL- 12 as a Gene Therapy Approach to Cancer Immunotherapy John A. Barrett Ph.D. Ziopharm Oncology, Boston MA 02129 Background & Rationale IL-12 in Oncology Tumors grow
More informationDISCLOSURES. Roche/MSD-Merck/Celgene: Research Funding
DISCLOSURES Roche/MSD-Merck/Celgene: Research Funding Roche/Celgene/AstraZeneca/Amgen/MSD/Novartis/Sanofi- Aventis/Pierre Fabré: Advisory Board or Consultant No conflict of interest with respect to this
More informationIMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust
IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent
More informationSupplementary Figure 1. ETBF activate Stat3 in B6 and Min mice colons
Supplementary Figure 1 ETBF activate Stat3 in B6 and Min mice colons a pstat3 controls Pos Neg ETBF 1 2 3 4 b pstat1 pstat2 pstat3 pstat4 pstat5 pstat6 Actin Figure Legend: (a) ETBF induce predominantly
More informationPersonalized Cancer Medicine. Conceptual,Organizational,Financial Challenges
Personalized Cancer Medicine Conceptual,Organizational,Financial Challenges SHANGHAI 6 July, 2012 What is breast cancer? The old perception The New Family of Diseases Perception / Molecular Portraits What
More informationCurrent Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology
Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology Overview Melanoma incidence and prevention Approach to surgical management of early melanoma Landscape of Advanced Melanoma Therapy
More informationBRAF inhibitors Anti-angiogenic therapy Other molecular targets Discussion
If you experience any technical difficulties call 8-274-939 or e-mail informed@commpartners.com Slides will advance automatically. You can also advance/ review the presentation using the control buttons
More informationState of the Art 3: Immunotherapy and Modulators of Apoptosis
State of the Art 3: Immunotherapy and Modulators of Apoptosis James Finke, PhD - Cleveland Clinic, Immunology Crystal Mackall, MD - NCI, Pediatric Oncology James Mier, MD - BIDMC, Medical Oncology Craig
More informationImmunotherapy on the Horizon: Adoptive Cell Therapy
Immunotherapy on the Horizon: Adoptive Cell Therapy Joseph I. Clark, MD, FACP Professor of Medicine Loyola University Chicago Stritch School of Medicine Maywood, IL June 23, 2016 Conflicts of Interest
More informationmtor and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2015 mtor and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic
More informationAdvances in Melanoma
Advances in Melanoma The Blue, the Black and the Ugly 1 Outline History of Melanoma Why be concerned? Skin cancer updates What s old? What s new (and why are Skin Tumor Group med oncs excited again)? What
More informationBRAF Inhibitors in Metastatic disease. Grant McArthur MB BS PhD Peter MacCallum Cancer Centre Melbourne, Australia
Inhibitors in Metastatic disease Grant McArthur MB BS PhD Peter MacCallum Cancer Centre Melbourne, Australia Disclosures Research Support Pfizer & Cellgene Consultant Provectus Mortality from Melanoma
More informationTherapeutic efficacy of MUC1- specific CTL and CD137 costimulation. mammary cancer model. Pinku Mukherjee & Sandra Gendler
Therapeutic efficacy of MUC1- specific CTL and CD137 costimulation in a spontaneous mammary cancer model Pinku Mukherjee & Sandra Gendler Goal of Immunotherapy Boosting the low level anti-tumor immune
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role
More informationNIH Public Access Author Manuscript Mol Oncol. Author manuscript; available in PMC 2015 March 01.
NIH Public Access Author Manuscript Published in final edited form as: Mol Oncol. 2014 March ; 8(2): 250 260. doi:10.1016/j.molonc.2013.11.005. COX-2 inhibition prevents the appearance of cutaneous squamous
More informationImmune response to infection
Immune response to infection Dr. Sandra Nitsche (Sandra.Nitsche@rub.de ) 20.06.2018 1 Course of acute infection Typical acute infection that is cleared by an adaptive immune reaction 1. invasion of pathogen
More informationScott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION
Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 13 Effector Responses: Cell- and Antibody-Mediated Immunity Copyright 2013 by W. H.
More information